Figure 5.

Expression of septin 7 and OPA1 are affected by administration of HDAC inhibitors. (A) Scheme of drug administration: cohorts were administered 10 days of vehicle (0d), 5 days of vehicle followed by 5 days of MS-275 (5d) or 10 days of MS-275 or SAHA (10d). (B and C) Total hippocampal lysates from mice that had obtained MS-275 injections or vehicle were western blotted against acetylated forms of H3K18, H3K14 and H4K12, against p35/p25, septin 7 and OPA1, and normalized against β-actin. (C) Acetylation of H3K18 was increased after MS-275 administration, indicating successful drug treatment. Acetylation of H3K14 and H4K12 were not changed, confirming the specificity of the drug. The expression of septin 7 and OPA1 was significantly increased after 10 days of MS-275 administration, while p35/p25 levels were unaltered. (D and E) After 10 days of SAHA treatment, p25 and septin 7 levels were significantly upregulated. SAHA increased acetylation of H3K18 as well as H4K12 in agreement with its unspecific inhibition of class I HDACs. Expression of p35, H3K14 and OPA1 were not affected by SAHA treatment (n = 6–8 per group; *P < 0.05; **P < 0.01; average ± SEM shown).